Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DelveInsight | PRODUCT CODE: 1259786

Cover Image

PUBLISHER: DelveInsight | PRODUCT CODE: 1259786

Acute ischemic stroke (AIS) - Epidemiology Forecast - 2032

Published: Pre-Order
PAGES: 112 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 3950
PDF (2-3 user license)
USD 5925
PDF (Site License)
USD 7900
PDF (Global License)
USD 11850

Add to Cart

Key Highlights

  • The incidence of ischemic stroke has been increasing in younger adults, largely driven by a rise in diabetes, obesity, and metabolic syndrome in this age group. A sedentary lifestyle is one of the major risk factors for an ischemic stroke.
  • Misdiagnosis and delayed diagnosis continue to be challenging for ischemic stroke patients and might lead to a rise in mortality rate.
  • The 7MM accounted for over 1.5 million cases of acute ischemic stroke in 2022. The US reported the highest number of cases of acute ischemic stroke, with more than 700,000 in 2022, owing to the long-term psychological, physical, and social consequences.
  • The risk of acute ischemic stroke is similar in men and women in the US. However, in EU4 and the UK, and Japan, it has been found that men are at a higher risk than women.
  • Assessments showed that the US accounted for less than 600,000 acute ischemic stroke cases in both males and females in 2022. While in Japan, males were affected more, accounting for nearly 100,000 cases compared to females (around 90,000 cases).

DelveInsight's'Acute Ischemic Stroke (AIS) - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of acute ischemic stroke (AIS) in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Acute Ischemic Stroke (AIS) Overview

Acute ischemic stroke (AIS) occurs due to the blockage in the artery resulting in reduced blood flow to the brain that damages and interrupts the brain functions. Every year around 5.5 million people die from stroke, making it the world's second leading cause of death. Moreover, a high burden of morbidity is also seen in stroke patients leaving nearly 50% of stroke survivors disabled. Of total stroke cases, approximately 70-85% of cases are attributed to ischemic stroke. Common signs and symptoms in patients with acute stroke include hemiparesis, sensory deficits, diplopia, dysarthria, and facial droop. Additionally, the symptoms commonly attributed to increased intracranial pressure, such as nausea, vomiting, headache, and blurred or double vision, may also provide evidence supporting a stroke. Based on the etiology, AIS is divided into four subtypes: 20% cardioembolic, 20% atherosclerosis (large artery disease), 25% lacunar (small vessel disease), and 5% other causes.

Continued in the report…..

Acute Ischemic Stroke (AIS) Diagnosis

For the diagnosis of acute ischemic stroke (AIS), detection is emphasized by the term "time is brain" as the delay in diagnosis can impact the treatment choice. The diagnosis is based on clinical features and data collected by tests such as brain imaging (computed tomography/MRI), cardiac imaging (echocardiography, among others), duplex imaging of extracranial arteries, arteriography, and laboratory assessments for a prothrombotic state. Additionally, the National Institutes of Health Stroke Scale (NIHSS) is widely used to assess the neurological severity of acute ischemic stroke. However, early stroke detection is still critical in rural areas and small clinics due to the unavailability of costly diagnostic tools. Also, the delay in diagnosis can worsen stroke and hamper treatment.

Further, atypical presenting symptoms associated with brain stem and cerebellar-posterior circulation can cause over, under, and misdiagnosis of stroke. Additionally, misdiagnosis can be a risk in young patients with ischemic stroke, leading to delayed recognition, preventing thrombolytic therapy, and increasing morbidity and mortality. Hence, misdiagnosis limits the opportunities for a better treatment outcome.

Nevertheless, the advances in diagnostic tools and equipment, continuous efforts in discovering blood-based biomarkers, and improving diagnosis would drive the growth of the acute ischemic stroke market. Heart and stroke screenings in developed countries will also contribute to market growth.

Further details related to country-based variations are provided in the reported…

Acute Ischemic Stroke (AIS) Epidemiology

As the market is derived using a patient-based model, the acute ischemic stroke (AIS) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed incidence cases of acute ischemic stroke, gender-specific cases of acute ischemic stroke, age-specific cases of acute ischemic stroke, type-specific cases of acute ischemic stroke in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2019 to 2032.

  • Among the 7MM, the US accounted for the highest number of cases of acute ischemic stroke, with more than 700,000 cases, in 2022, owing to the long-term psychological, physical, and social consequences among the population.
  • Among the EU4 and the UK, Germany accounted for the highest number of acute ischemic stroke cases (around 250,000). On the contrary, Spain accounted for the least cases in 2022.
  • Assessments showed that the US accounted for less than 600,000 acute ischemic stroke cases in both males and females in 2022. While in Japan, more males were affected by acute ischemic stroke accounting for nearly 100,000 cases, and females for around 90,000 cases in 2022.
  • In Japan, there were around 60,000 cases of large artery, 58,000 cases of small artery occlusions, 77,000 cases of cardioembolism, and 35,000 cases of other/undetermined types in 2022.

Country-wise Acute Ischemic Stroke Epidemiology

The report includes the total diagnosed incident cases of acute ischemic stroke in the 7MM countries, estimated to be over 1.6 million in 2022. The seven major markets cover the following:

  • United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan

Scope of the Report:

  • The acute ischemic stroke (AIS) report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
  • The Acute Ischemic Stroke (AIS) Epidemiology Report and Model provide an overview of the risk factors and global trends of acute ischemic stroke (AIS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of acute ischemic stroke (AIS) in seven major markets covering the United States, EU4 (Germany, Spain, France, and Italy) and the UK, and Japan.
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of acute ischemic stroke.
  • The report provides the segmentation of the acute ischemic stroke epidemiology by diagnosed incident cases of acute ischemic stroke in the 7MM.
  • The report provides the segmentation of the acute ischemic stroke epidemiology by gender-specific cases of acute ischemic stroke in the 7MM.
  • The report provides the segmentation of the acute ischemic stroke epidemiology by age-specific cases of acute ischemic stroke in the 7MM.
  • The report provides the segmentation of the acute ischemic stroke epidemiology by type-specific cases of acute ischemic stroke in the 7MM.

KOL Views

  • To keep up with current market trends, we interviewed KOLs and obtained SME's opinions through primary research to fill the data gaps and validate our secondary research. Their opinion helped understand and validate current and emerging treatment patterns or acute ischemic stroke (AIS) market trends. This supported the identification of potential novel treatments by identifying the overall scenario of the market and the unmet needs.
  • Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as Hotchkiss Brain Institute Europe, MD American Psychiatric Association, Director of Immunology England, MD University of Colorado Anschutz Medical Campus, etc., were contacted. Their opinion helped understand and validate current and emerging therapies and treatment patterns or acute ischemic stroke market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Key Questions Answered

  • What will be the growth opportunities in the 7MM for the patient population pertaining to acute ischemic stroke?
  • What are the key findings pertaining to acute ischemic stroke epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019-2032)?
  • What would be the total number of patients with acute ischemic stroke across the 7MM forecast period (2019-2032)?
  • Among the EU4 and the UK, which country will have the highest number of patients during the forecast period (2019-2032)?
  • At what CAGR is the patient population expected to grow in the 7MM forecast period (2019-2032)?
  • What are acute ischemic stroke's disease risks, burdens, and unmet needs?
  • What are the currently available treatments for acute ischemic stroke?

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan

Study Period: 2019-2032

Product Code: DIEI0245

Table of Contents

1. Key Insights

2. Report Introduction

3. Acute Ischemic Stroke (AIS) Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of AIS in 2019
  • 3.2. Market Share (%) Distribution of AIS in 2032

4. Executive Summary of Acute Ischemic Stroke (AIS)

5. Key Events

6. Epidemiology and Patient Population

7. Disease Background and Overview

  • 7.1. Introduction
  • 7.2. Classification of Stroke
  • 7.3. Clinical Manifestations
  • 7.4. Etiology and Risk Factors
  • 7.5. Pathophysiology of Ischemic Shock
  • 7.6. Comorbidities Associated With AIS
  • 7.7. Diagnosis of Ischemic Stroke
    • 7.7.1. Differential Diagnosis
  • 7.8. Management of Acute Ischemic Stroke
  • 7.9. Clinical Guidelines
    • 7.9.1. Guidelines for the early management of patients with acute ischemic stroke 2019: American Stroke Association
    • 7.9.2. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association
    • 7.9.3. Japan Stroke Society Guideline 2021 for the Treatment of Stroke
    • 7.9.4. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke

8. Epidemiology and Patient Population

  • 8.1. Key Findings
  • 8.2. Assumptions and Rationale
  • 8.3. Total Diagnosed Incident Cases of AIS in the 7MM
  • 8.4. The US
    • 8.4.1. Diagnosed incident cases of Acute Ischemic Stroke (AIS) in the US
    • 8.4.2. Gender-specific cases of Acute Ischemic Stroke (AIS) in the US
    • 8.4.3. Age-specific cases of Acute Ischemic Stroke (AIS) in the US
    • 8.4.4. Type-specific cases of Acute Ischemic Stroke (AIS) in the US
  • 8.5. EU4 and the UK
    • 8.5.1. Diagnosed Incident Cases of Acute Ischemic Stroke (AIS) in EU4 and the UK
    • 8.5.2. Gender-specific cases of Acute Ischemic Stroke (AIS) in EU4 and the UK
    • 8.5.3. Age-specific cases of Acute Ischemic Stroke (AIS) in EU4 and the UK
    • 8.5.4. Type-specific cases of Acute Ischemic Stroke (AIS) in EU4 and the UK
  • 8.6. Japan
    • 8.6.1. Diagnosed incident cases of Acute Ischemic Stroke (AIS) in Japan
    • 8.6.2. Gender-specific cases of Acute Ischemic Stroke (AIS) in Japan
    • 8.6.3. Age-specific cases of Acute Ischemic Stroke (AIS) in Japan
    • 8.6.4. Type-specific cases of Acute Ischemic Stroke (AIS) in Japan

9. SWOT Analysis

10. KOL Views

11. Unmet Needs

12. Market Access

  • 12.1. Disease Burden Studies
  • 12.2. Cigna Health Insurance
  • 12.3. The US
    • 12.3.1. Medicare thrombolytic agent coverage
    • 12.3.2. Patient assistance programs for ACTIVASE
  • 12.4. Europe
    • 12.4.1. Health insurers, authorities, and support groups
  • 12.5. Japan

13. Appendix

  • 13.1. Bibliography
  • 13.2. Acronyms and Abbreviations
  • 13.3. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

Product Code: DIEI0245

List of Tables

  • Table 1: Summary of AIS, Market, and Epidemiology (2019-2032)
  • Table 2: Key Events
  • Table 3: Classification of Grade of Recommendation by the Committee (2021)
  • Table 4: Classification of Level of Evidence (LOE) of the Recommendations by the Committee (2021)
  • Table 5: Total Diagnosed Incident Population of AIS in the 7MM (2019-2032)
  • Table 6: Total Diagnosed Prevalent Cases of AIS in the 7MM (2019-2032)
  • Table 7: Total Diagnosed Incident Cases of AIS in the US (2019-2032)
  • Table 8: Gender-specific Cases of AIS in the US (2019-2032)
  • Table 9: Age-specific Cases of AIS in the US (2019-2032)
  • Table 10: Type-specific Cases of AIS in the US (2019-2032)
  • Table 11: Total Diagnosed Incident Cases of AIS in EU4 and the UK (2019-2032)
  • Table 12: Gender-specific Cases of AIS in EU4 and the UK (2019-2032)
  • Table 13: Age-specific Cases of AIS in EU4 and the UK (2019-2032)
  • Table 14: Type-specific Cases of AIS in EU4 and the UK (2019-2032)
  • Table 15: Total Diagnosed Incident Cases of AIS in Japan (2019-2032)
  • Table 16: Gender-specific Cases of AIS in Japan (2019-2032)
  • Table 17: Age-specific Cases of AIS in Japan (2019-2032)
  • Table 18: Type-specific Cases of AIS in Japan (2019-2032)

List of Figures

  • Figure 1: Clinical Features of Ischemic Stroke
  • Figure 2: Blood Supply Disruption and Ischemic Stroke Pathogenesis
  • Figure 3: Schematic Visualization of the Ideal Therapeutic Approach Toward AIS
  • Figure 4: Algorithm for Evaluating Patients With a Clinical Diagnosis of Stroke to Optimize the Prevention of Recurrent Ischemic Stroke
  • Figure 5: Total Diagnosed Incident Population of AIS in the 7MM (2019-2032)
  • Figure 6: Total Diagnosed Incident Cases of AIS in the US (2019-2032)
  • Figure 7: Gender-specific Cases of AIS in the US (2019-2032)
  • Figure 8: Age-specific Cases of AIS in the US (2019-2032)
  • Figure 9: Type-specific Cases of AIS in the US (2019-2032)
  • Figure 10: Total Diagnosed Incident Cases of AIS in EU4 and the UK (2019-2032)
  • Figure 11: Gender-specific Cases of AIS in EU4 and the UK (2019-2032)
  • Figure 12: Age-specific Cases of AIS in EU4 and the UK (2019-2032)
  • Figure 13: Type-specific Cases of AIS in EU4 and the UK (2019-2032)
  • Figure 14: Total Diagnosed Incident Cases of AIS in Japan (2019-2032)
  • Figure 15: Gender-specific Cases of AIS in Japan (2019-2032)
  • Figure 16: Age-specific Cases of AIS in Japan (2019-2032)
  • Figure 17: Type-specific Cases of AIS in Japan (2019-2032)
  • Figure 18: Mechanism of Action of Scp776
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!